# Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

> clinical trial · VERIFIED · 2026-07-30

Status: RECRUITING · Sponsor: AstraZeneca · Condition: Advanced Breast Cancer

- Company: AstraZeneca
- Sector: Advanced Breast Cancer
- Primary source: https://clinicaltrials.gov/study/NCT06380751

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.